Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing - Wikidata - wikimedia - TriplyDB

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

http://www.wikidata.org/entity/Q26784507

about

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics.Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.Clinical Trial Design in Juvenile Idiopathic Arthritis.The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients Advances and challenges in hereditary cancer pharmacogenetics.The impact of the UGT1A1*60 allele on bilirubin serum concentrations.Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Integrating pharmacogenomics into electronic health records with clinical decision support.Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele.Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele.Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.Comparison of genome sequencing and clinical genotyping for pharmacogenes.Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Biomarkers of adverse drug reactions.Clinical Pharmacology & Therapeutics: Past, Present, and Future.Germline genetic variants with implications for disease risk and therapeutic outcomes.Genetic Testing in Clinical Settings.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics UGT1A1 (TA)n promoter genotype: Diagnostic and population pharmacogenetic marker in Serbia

P2860

Q28069383-C0D0516A-4B72-4AE3-BDB1-51A17E9B80F7 Q28078760-180376AB-C679-445A-92FC-3AC9D240DE84 Q28079766-7C2CB3CA-26F5-45D2-B29A-26179E3D1D20 Q28552832-7D60557A-47CE-462F-85B0-8F6D27C9052C Q33877987-6D2C0956-2CF9-4F34-9217-0B92746DAA1E Q37597647-FF66E257-9800-4011-9E6F-43F6D19E475A Q37725310-14F04C46-B7AD-4582-80AE-E80F99F95829 Q38671265-ED3B295F-D6D7-4693-8E90-D00B652F5F63 Q38760559-1D095394-A5E5-4D30-B974-46FC937EB9B7 Q38948499-506E614D-293A-44FF-A8A6-5844E1655363 Q39038260-32653D3A-E6F6-4798-9B29-4BA1973CA9E8 Q39062032-DB27C7E6-226A-4C88-97E6-BBA7D357424F Q39173298-B2BE6744-999D-4F9E-921C-B15930BA5F7F Q39173300-C5B63AE7-538B-4A55-868C-E7C177899166 Q40052062-303DB682-3B7E-462D-89A2-CB305CB58F20 Q40089973-BB762402-9565-4145-B330-F5F4D744156B Q40474323-E5443A1A-7802-4E2F-852A-B60F7E1AD425 Q42335970-5D00CD78-6855-4162-93BD-DFD2E2BDCF13 Q46776696-D7D9202F-2482-42C6-A295-6F330435EDA3 Q47128107-13CC41DF-6352-4752-8A9F-79694CB0BDFB Q47632215-4D82C138-4FFE-4D45-8A96-CAAFACF37DCF Q47906608-DDF473FB-D6E9-413C-862A-2A0DE838A4CC Q47928481-80CE934C-9911-4956-9953-C5181F379F11 Q48059492-C6225E2B-F121-4D31-A16F-4D1E8AB164EC Q48100807-205EFBBC-9DDD-4020-B46F-43EFD0376976 Q52588359-00B54922-E2F8-41B2-A41B-0341998D3F65 Q57403878-4E3E9048-7605-48E8-98A9-D6B8D84EB7DE Q58695636-53E6ADD4-950E-4427-9265-EF576AFB80BF

P2860

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

http://www.wikidata.org/entity/Q26784507

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@ast

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@en

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@nl

type

label

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@ast

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@en

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@ast

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@en

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@nl

P1433

Q26784507-18424572-EC25-40EC-B071-1BF7FAC10565

P1476

Q26784507-BB79744C-FED7-40D2-ACAE-A2D83A04B8BE

P2093

Q26784507-07F710A5-3E18-499A-9AC0-13BE707530B5

Q26784507-080EA072-DACA-4F9A-A8BC-82DB5E760F97

Q26784507-4BA577E2-2C26-4C5D-938C-8A78A9365929

Q26784507-5C87A1F8-CDC8-4C82-8BE3-11F6FD18B36E

Q26784507-7289CD28-662D-4CB3-BD5B-48E53ADEA340

Q26784507-73F3D233-F531-46AC-A6C5-BF84A1F871CF

Q26784507-96ECF1A0-08E7-49D5-854C-7D42FAD25EE1

Q26784507-9AA2D201-D1EA-4686-B7F2-DC4B487098BB

Q26784507-A2866524-AE03-4E68-93BB-9EA1AE59B58A

Q26784507-C148819D-41D6-4BA5-90B3-F14A1F722108

P2860

Q26784507-06152520-3D5E-4734-95A0-64D971B7AE50

Q26784507-067009CA-2BF7-41AD-B8EF-04B1EC40B8E7

Q26784507-0F2263AC-6A9A-46D7-88F6-5BCE4D4C72B9

Q26784507-140185EB-EB31-4340-AE7D-4522866C1143

Q26784507-165D4975-8972-4F5B-AE4F-0196EBA1D035

Q26784507-2510FC25-E787-42B9-9AD6-63E6D3A01CCA

Q26784507-35C461F2-FB7C-458E-BD9E-AEF9EDEF5CCF

Q26784507-4115C14D-A810-4EC6-BA37-744F1EC759F2

Q26784507-48E50383-AEBE-4853-9F54-99B40C882EAD

Q26784507-4E50A734-D3B5-49F2-8B58-47AC3F7BB231

P304

Q26784507-3881AA04-07E1-4A67-8BFE-E55974A546B2

P31

Q26784507-7259184B-DF58-470E-A0D1-4BA232505085

P3181

Q26784507-D07D9320-E559-4E49-A1F8-D8B2A86B08A2

P356

Q26784507-670F0B88-2C07-45CA-8D2F-2CAB0A573A76

P407

Q26784507-0379847B-45E5-43E7-9EA8-1B5098E2ECC9

P433

Q26784507-CD656B7C-07D4-487A-939A-74558C36F965

P478

Q26784507-3BDF0744-A17E-4D81-8FD9-EE28D5D79DB8

P50

Q26784507-DA5DB406-A08A-4503-BE97-9E3C1DDE939E

P577

Q26784507-46B9E6E8-391F-4175-ABA2-62AD1C018F46

P698

Q26784507-9418D8D8-57A8-4F50-9CFA-17E9B46E61C3

P932

Q26784507-695805C2-281A-4748-B182-64A49BD36862

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... 1A1 and Atazanavir Prescribing

@en

P2093

A H Gaur

http://www.w3.org/2001/XMLSchema#string

B R Schackman

http://www.w3.org/2001/XMLSchema#string

C E Haidar

http://www.w3.org/2001/XMLSchema#string

C Guillemette

http://www.w3.org/2001/XMLSchema#string

D W Haas

http://www.w3.org/2001/XMLSchema#string

J L Lennox

http://www.w3.org/2001/XMLSchema#string

K E Caudle

http://www.w3.org/2001/XMLSchema#string

M Alvarellos

http://www.w3.org/2001/XMLSchema#string

M H Court

http://www.w3.org/2001/XMLSchema#string

M J Ratain

http://www.w3.org/2001/XMLSchema#string

P2860

PharmGKB summary: very important pharmacogene information for UGT1A1

Cruciferous vegetable feeding alters UGT1A1 activity: diet- and genotype-dependent changes in serum bilirubin in a controlled feeding trial

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia

Genome-wide association meta-analysis for total serum bilirubin levels

Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype

Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man

Developmental aspects of human hepatic drug glucuronidation in young children and adults

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

Genome-wide association of serum bilirubin levels in Korean population.

P304

363-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2886774

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/CPT.269

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Michelle Whirl-Carrillo

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26417955

http://www.w3.org/2001/XMLSchema#string

P932

4785051

http://www.w3.org/2001/XMLSchema#string